CENPN and breast cancer: Immunohistochemistry scores were utilized to statistically analyze the clinicopathological data of the patients, which revealed that CENPN overexpression was associated with higher T-stage, N-stage, and pathological stage (Fig. 5C, D and E) and was highly expressed in ER (Fig. 5H), PR (Fig. 5G), and triple-negative breast cancer patients than in other types of breast cancer (Fig. 5F), and these results were generally consistent with those obtained from bioinformatic analysis.